Skip to main content
Erschienen in: Journal of Cancer Education 4/2015

01.12.2015 | Reflection

The Evolution of Undergraduate Medical Student Research Activities: Personal Experience of a Developing Nation’s Uprise

verfasst von: Mohamed Amgad, Emad Shash

Erschienen in: Journal of Cancer Education | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Excerpt

Revolutions are swift, while evolution is typically a slow, incremental process. One of the most notable things that happened after the Egyptian 2011 revolution was the explosive uprising of youth. Regardless of the political turn of events, which is surely not the subject of this piece, it was becoming increasingly clear that something beyond politics was radically changing the academic landscape, particularly among university students. What started as a “revolutionary” interest in science and research quickly transformed into a continuously changing “evolutionary” process. As a final-year medical student who spent half of his medical school before the revolution, and half of it after the political turmoil, I was lucky to be one of the earliest “experiments” demonstrating the value of strong mentorship on developing an early aptitude for research. One year before the revolution, an oncology summer rotation was developed at the National Cancer Institute (NCI, Cairo University), designed to test the applicability of incorporating oncology rotations into the core medical curriculum in medical schools in developing countries [1]. I joined the course in its second year; the year of the revolution. The course instructor—who later became my long-term research mentor and is co-authoring this opinion piece—integrated an academic writing component into the rotation, as a way to stay in par with the then-budding interest in research among the revolution youngsters. The result was a published literature review article that he and I co-authored on the very same topic that the oncology summer school addressed: oncology education for medical students in developing countries [2]. …
Literatur
3.
Zurück zum Zitat Amgad M, Man Kin Tsui M, Liptrott SJ, Shash E. Medical student research: an integrated mixed-methods systematic review and meta-analysis. Manalo E, editor. PLoS One. 2015;10: e0127470. doi:10.1371/journal.pone.0127470 Amgad M, Man Kin Tsui M, Liptrott SJ, Shash E. Medical student research: an integrated mixed-methods systematic review and meta-analysis. Manalo E, editor. PLoS One. 2015;10: e0127470. doi:10.1371/journal.pone.0127470
9.
Zurück zum Zitat Baig SA, Hasan SA, Ahmed SM, Ejaz K, Aziz S, Dohadhwala NA (2013) Reasons behind the increase in research activities among medical students of Karachi, Pakistan, a low-income country. Educ Health (Abingdon) 26:117–121. doi:10.4103/1357-6283.120705 Baig SA, Hasan SA, Ahmed SM, Ejaz K, Aziz S, Dohadhwala NA (2013) Reasons behind the increase in research activities among medical students of Karachi, Pakistan, a low-income country. Educ Health (Abingdon) 26:117–121. doi:10.​4103/​1357-6283.​120705
Metadaten
Titel
The Evolution of Undergraduate Medical Student Research Activities: Personal Experience of a Developing Nation’s Uprise
verfasst von
Mohamed Amgad
Emad Shash
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Journal of Cancer Education / Ausgabe 4/2015
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-015-0923-z

Weitere Artikel der Ausgabe 4/2015

Journal of Cancer Education 4/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.